Table 4:
A Comparison of Health Care Resource Utilization During the Follow-up Period Comparing Black Patients With CD or UC With White Patients in Unadjusted and Adjusted Analyses
| Unadjusted Odds Ratio, CD (95% CI) |
Adjusted Odds Ratio,a CD (95% CI) |
Unadjusted Odds Ratio, UC (95% CI) | Adjusted Odds Ratio,a UC (95% CI) |
|
|---|---|---|---|---|
| IBD-related surgery | 0.66 (0.39–1.11) | 0.62 (0.37–1.05) | 0.19 (0.03–1.38) | 0.18 (0.02–1.29) |
| Hospitalization | 1.14 (0.84–1.54) | 1.09 (0.80–1.48) | 0.96 (0.53–1.73) | 0.93 (0.51–1.70) |
| Initiation of anti-TNF | 1.83 (1.08–3.08) | 1.85 (1.09–3.14) | 1.65 (0.65–4.20) | 1.42 (0.55–3.69) |
| Initiation of combination therapy | 0.78 (0.24–2.52) | 0.71 (0.22–2.30) | 2.18 (0.50–9.42) | 1.75 (0.40–7.78) |
| Initiation of a thiopurine | 1.22 (0.61–2.44) | 1.11 (0.55–2.25) | 0.85 (0.20–3.54) | 0.72 (0.17–3.04) |
| Initiation of methotrexate | 1.29 (0.56–3.01) | 1.24 (0.53–2.90) | 2.51 (0.58–10.9) | 2.29 (0.51–10.2) |
| New steroid therapy | 2.05 (0.92–4.58) | 2.07 (0.92–4.65) | N/Ab | N/Ab |
aAdjusted for sex, age, tobacco use, time since diagnosis, and Montreal classification of disease at baseline.
bNo black patients with UC received a new prescription for steroids during the follow-up period.